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Preface
The Nordic Council is an intergovernmental collaborative body for the five
countries, Denmark, Finland, Iceland, Norway, and Sweden. One of the
committees, the Nordic Senior Executive Committee for Occupational Environ-
mental Matters, initiated a project in order to produce criteria documents to be
used by the regulatory authorities in the Nordic countries as a scientific basis for
the setting of national occupational exposure limits.
The management of the project is given to an expert group. At present the
Nordic Expert Group consists of the following members:
Gunnar Johanson
(chairman)
Karolinska Institutet and National Institute for
Working Life, Sweden
Vidir Kristjansson Administration of Occupational Safety and Health,
Iceland
Kai Savolainen Finnish Institute of Occupational Health, Finland
Vidar Skaug National Institute of Occupational Health, Norway
Karin Sørig Hougaard National Institute of Occupational Health, Denmark
For each document an author is appointed by the Expert Group and the national
member acts as a referent. The author searches for literature in different data
bases such as HSELINE, Medline and NIOSHTIC. Information from other
sources such as WHO, NIOSH and the Dutch Expert Committee on Occupational
Standards is also used as are handbooks such as Patty’s Industrial Hygiene and
Toxicology. Evaluation is made of all relevant scientific original literature found.
In exceptional cases information from documents difficult to access is used.
The document aims at establishing dose-response/dose-effect relationships and
defining a critical effect based only on the scientific literature. The task is not to
give a proposal for a numerical occupational exposure limit value.
The evaluation of the literature and the drafting of this document on penicillins
was made by Dr Gregory Moore, the Swedish Chemicals Inspectorate and
Dr Olle Nygren, the National Institute for Working Life, Sweden. The draft
document was discussed within the Expert Group and the final version was
accepted by the Nordic Expert Group April 20, 2001, as its document. Editorial
work and technical editing was performed by the Group’s Scientific Secretaries,
Jill Järnberg and Anna-Karin Alexandrie, at the National Institute for Working
Life in Sweden.
All criteria documents produced by the Nordic Expert group may be down-
loaded from www.nordicexpertgroup.org.
We acknowledge the Nordic Council for its financial support of this project.
Abbreviations
BPO  benzylpenicilloyl
HPLC high performance liquid chromatography
KPG crystalline potassium penicillin G
OECD Organisation for Economic Co-operation and Development
SI stimulation index
TLV threshold limit value
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11. Introduction
Penicillins are a class of antibiotic produced by some members of the genus
Penicillium (14, 45). In brief, in 1929 Fleming discovered penicillin and
recognised its antibacterial properties (25). Penicillin and derivatives were
produced by fermentation by the end of the 1940s. The penicillin family of
compounds, however, has been a significant source of in-plant medical problems
since their large scale production began in the late 1940s (83). Medical problems
have also occurred in other occupations due to inhalation and dermal exposure
(19, 29, 90).
This document considers sensitisation in workers occupationally exposed to
manufactured penicillins by the inhalation and dermal routes. To determine all the
possible different types of penicillins that may give rise to occupational exposure
in the Nordic countries all of the penicillin containing products available on the
USA and UK markets were compared with those found on the Swedish market.
Most of the USA and UK products were found on the Swedish market. Hence, to
rationalise this criteria document, products on the Swedish market are used as a
surrogate for all Nordic countries. It is, however, recognised that for the purpose
of risk reduction and/or management at that time, an exact itinerary of all products
on each Nordic country’s market may be more relevant.
Adverse effects observed in patients (general public) exposed via inhalation
and dermal exposure routes are also considered when deemed relevant. Type II
and III hypersensitivity are not addressed in this document, as they are apparently
associated with other routes of exposure e.g. oral, intravenous. Similarly, only
information from animal experiments conducted by the inhalation and dermal
routes are considered: animal experiments performed by other routes are often
conducted for clinical and pharmacological research purposes. It is also assumed
that, since penicillins are registered pharmaceutical and veterinarian preparations
used for the treatment of bacterial infections, additional unpublished information
must be available to have satisfied the different regulatory requirements for regi-
stration of penicillins by exposure routes both currently used and discontinued.
Administration of penicillins by topical and inhalatory routes is not currently
approved, as hypersensitivity effects have been demonstrated in man.
2. Substance identification and physical and chemical properties
Penicillins can be classified in several ways. Either as natural or synthetic or with
regard to their resistance to acids or penicillinases or as having more or less broad
spectrum properties (10). The penicillins have a fused ß-lactam thiazolidine ring
system in common. It is known as 6-aminopenicillanic acid, and vary in the amino
(R1) and carboxylic (R2) side chains (Figure 1).
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Figure 1. The general structure of penicillins.
The inherent strain of the N-atom in the four membered ß-lactam ring and the
distortion of the planar geometry in the bicyclic system are commonly regarded as
an essential factor to the high reactivity of penicillins and contributing to their
antibacterial properties. Besides the ß-lactam ring, the side chains are important
factors, essential for the biological activity. The dissociation constant (pKa) for
penicillins is about 2.6-2.8 (37), which indicates a fairly strong acidity. Informa-
tion regarding other physical properties of penicillins has been presented by
Florey, Van Krimpen et al. and Hou et al. (27, 37, 86).
In the activity and degradation of penicillins the ß-lactam ring plays an essential
role. In neutral or alkaline medium, the ring can be opened either by hydroxide
ions or by other nucleophils. Both reaction paths lead via different intermediates
to penicilloic acid (86). Usually the rates of alkaline hydrolysis are significantly
larger than those of acid hydrolysis (37). Transition metals ions (e.g. Cu2+) cause a
very large increase in the rate of aminolysis and hydrolysis of penicillins.
Penicillins are used for treatment of a large number of bacterial infections in
humans and animals (4). The primary mechanism of action is inhibition of the
bacterial cell wall synthesis. Penicillins have a structural analogy of the ß-lactam
ring with D-alanyl-D-alanine, which terminates free N-acetylmuramic acid, a part
of the glycan structure of the bacterial cell wall. Gram-positive bacteria are more
sensitive to penicillin than gram-negative bacteria as they have higher glycan
content (up to 50% cf. 1-10%)(86).
3. Occurrence, production and use
3.1 Volumes - production, export, import, and use
Penicillin is produced and handled in the Nordic countries but because penicillin
is registered as a pharmaceutical and veterinarian product information concerning
production, use, import and export volumes is confidential information in the
Nordic countries and thus cannot be detailed in this document. However, there are
some published information on the use of penicillins in humans and animals.
The sales of penicillin for human use in Sweden during 1999 were 8.1 daily
doses per 1 000 inhabitants (3).
Total usage of penicillins in animals in Sweden between 1988 and 1993 has
been documented by Björnerot and Tysén (9). In 1993, 13.2 tonnes of benzyl-
penicillin (Table 1 and Appendix 1) were used compared to 11.6 tonnes in 1988.
On average 97% of benzylpenicillin was injectable. Also in 1993, 0.86 tonnes of
3ampicillin/amoxycillin (Table 1 and Appendix 1) were used, an increase from
0.65 tonnes in 1988.
3.2 Production and use
There are six naturally occurring penicillins, but only benzylpenicillin (Penicillin
G; Table 1 and Appendix 1), and phenoxymethylpenicillin (Penicillin V; Table 1
and Appendix 1) are widely used as anti-infective agents. The ß-lactam base is
microbiologically produced (86) and is subsequently used to produce derivatised
penicillins (Table 1 and Appendix 1).
In the production of penicillin by fungi Penicillium chrysogenum, many
biological, chemical, and technical factors influence the growth of the cells and
product formation. Synthesis of β-lactam-antibiotics is a complex reaction system
coupled with both catabolism and anabolism, and undergoes various kinds of
metabolic regulation (8). Because bacteria may develop resistance to penicillins
used in treatment, different penicillin analogues have been developed to overcome
this problem and extend the antibiotic spectrum (86). Consequently, there are a
large number of antibiotics available requiring different processes for formation.
Intermediate use of penicillin bases for the production of penicillin derivatives by
chemical synthesis is in this document not regarded as use but as production of
penicillins. This may be a captive intermediate use i.e. on the same site of
production by a near by sister company, or by a second-site. The use of penicillin
derivatives in the production of end-products by formulation is also regarded as
production of penicillins rather than use. This may occur on-site or at a secondary
site. Handling activities are also regarded as production, e.g. packaging. It has,
however, not been possible to obtain data on the number of sites where penicillins
are produced, as there are no site-specific details available for any of the produc-
tion units in the Nordic countries.
Several derivatised penicillins are currently registered for use in Sweden.
Table 1 shows the penicillins, with commonly used trivial name, CAS number,
molecular formula, and weight, currently registered by Medical Products Agency
in Sweden (54). Appendix 1 contains more comprehensive information regarding
physical and chemical properties for these penicillin derivatives.
For human use, types of penicillin preparations that are currently used include
oral solids (tablets, capsules), and oral solutions (mixtures, drops, injectibles,
infusions). In the past, ointments, powders, sprays, lozengers, suppositories, and
vaginal bougies have been used (56, 57, 88). For animal use, penicillins are used
in tablets, mixtures, injections, and intra-mammary preparations. In the Nordic
countries penicillins are prescription drugs and cannot be obtained by across-the-
counter sales. In Sweden, given to animals penicillins are only allowed to be used
for medication and not as growth stimulation or for prophylactic purposes.
4Table 1. Penicillin derivatives currently used in Sweden (54).
Trivial name CAS
number
Molecular formula Molecular
weight
Procaine benzylpenicillin 54-35-3 C16H18N2O4S.C13H20N2O2. 571
Ampicillin sodium salt 69-52-3 C16H19N3O4S.Na 372
Benzylpenicillin sodium salt 69-57-8 C16H18N2O4S.Na 357
Penicillin V potassium salt 132-98-9 C16H18N2O5S.K 389
Cloxacillin sodium salt 642-78-4 C19H18ClN3O5S.Na 459
Benethamine penicillin 751-84-8 C16H18N2O4S.C15H17N 546
Penicillin G benzathine 1538-09-6 (C16H18N2O4S)2.C16H20N2 909
Penicillin G diethylaminoethyl ester 3689-73-4 C22H31N3O4S 434
Procaine penicillin 6130-64-9 C16H18N2O4S.C13H20N2O2.H2O 589
Cloxacillin sodium monohydrate 7081-44-9 C19H17ClN3O5S.Na.H20 476
Dicloxacillin sodium salt hydrate 13412-64-1 C19H16Cl2N3O5S.Na.H2O 510
Globacillin 17243-38-8 C16H17N5O4S 375
Pivampicillin hydrochloride 26309-95-5 C22H29N3O6S.HCl 500
Pivamdinocillin 32886-97-8 C21H33N3O5S 440
Selexid 32887-01-7 C15H23N3O3S 325
Pivmecillinam hydrochloride 32887-03-9 C21H33N3O5S.HCl 476
Ampicillin pivaloyloxymethyl ester 33817-20-8 C22H29N3O6S 464
Becampicillin hydrochloride 37661-08-8 C21H27N3O7S.HCl 502
Flucloxacillin 58486-36-5 (C19H16ClFN3O5S)2.Mg.8H2O 1 074
Amoxicillin trihydrate 61336-70-7 C16H19N3O5S.3H2O 419
4. Occupational exposure data
4.1 Environmental monitoring
Data on quantitative monitoring of penicillins in work place air are few. In three
studies personnel air monitoring have been conducted: two in the USA determi-
ning total and respirable penicillin dust in the work place during manufacture and
one in Sweden determining respirable dust during the preparation of an oral
solution at the pharmacy.
Hanke and Patnode studied the total and respirable dust in a penicillin drug
factory (32). The total dust concentration was determined using pre-weighed
membrane filters and the respirable dust was collected using a 10 mm cyclone
with a flow rate of 1.7 litres/minute. The result showed dust levels not exceeding
the threshold limit value (TLV) for various dust types. Shmunes et al. surveyed
penicillins in a factory and determined the total dust concentration by sampling on
membrane filters with a pore size of 0.8 µm (83). They did not report marked
levels in comparison with the various TLVs for different types of dust (83).
5In a study conducted at the Central Laboratory of the National Corporation of
Swedish Pharmacies, the emission of dust was investigated during preparation of
penicillin formulations (26). The particle size distribution and airborne dust levels
were measured during preparation of Imacillin® and Pondicillin®. The monitoring
was conducted during the preparation of a penicillin solution for 5 minutes. The
particle size characterisation showed that the dust had a particle size below 3 µm.
The airborne emission was determined for Imacillin® by sampling on membrane
filter and analysis by traditional microbiology technique. The average level of
Imacillin® was 1.2 µg/m3/5 minutes sampling (range 0.69-2.9) (26).
A semi-quantitative method using Petri dishes inoculated with test organisms
on agar gel has been used to survey airborne antibiotics in the manufacturing
workplace (61). The bacterial strain used was Bacillus stearothermophilus var.
calido lactis. The Petri dishes were placed out at different work areas during each
work episode, which could have a duration of one to five hours. After exposure at
the work areas the Petri dishes were incubated and inspected. To determine that
growth inhibition was specifically due to penicillins and thus minimise false
positives being included, one half of each plate was treated with penicillinase. The
number of inhibition zones was recorded to determine the degree of exposure:
<5/20 inhibition zones was classified as "low exposure" and >5/20 inhibition
zones as "high exposure" (61).
No others reports on specific studies of airborne penicillins have been found.
All the studies above lack specificity since correlation calculations between
airborne penicillins and health effects have been based on the total or the respi-
rable dust level assuming all dust emanates from penicillins. In some cases this
assumption may be adequate, e.g. in pharmaceutical industry production situations
where the only dust source is during the handling of dry penicillins. However, in
many other cases such an assumption would not be acceptable since there would
be significant misjudgement of the airborne penicillin concentration from the total
dust or respirable dust level. The lack of reliable studies on airborne penicillins
emphasises the need for the development of new robust methods for measuring
penicillins in workplace air.
4.2 Groups occupationally exposed
Present day exposure information relevant for different occupational groups in the
Nordic countries either does not exist or is not available in a published form for
assessment in this document. It is, therefore, not possible to estimate the number
of workers that may be exposed to penicillins and the extent of their exposure.
However, several occupational groups potentially exposed to penicillins are
postulated. The possibility also exists that other groups of workers, not identified
in this assessment, may be exposed to penicillins. For instance, exposure may
occur when handling penicillin contaminated materials such as hospital laundry,
medical waste and other waste disposal.
Penicillin is a solid powder that can form dusts during handling. Also solutions
of water soluble and insoluble penicillins are prepared. Formation of aerosols of
6penicillins would also be expected. Penicillin's vapour pressure is very low,
however, it is possible that a low level of exposure from the gas phase may occur
– the characteristic odour of many penicillins is distinct. Hence, the main forms of
penicillin that will result in exposure are dust, solutions, and aerosols. However,
due to the sensitivity of some individuals it cannot be ruled out that penicillin
vapours may elicit reactions in sensitised individuals.
Several occupational groups may be exposed to penicillin:
Workers producing penicillin and end-products are likely to be exposed to
penicillin in different physical forms mainly via the inhalation and dermal routes.
Exposure would be expected to occur during fermentation, chemical synthesis
of derivatives and formulation of end-products. The fermentation process may
result in exposure to penicillin dusts, solutions, and aerosols during routine
procedures such as loading, sampling, maintenance, packing, storage etc. In a
review by Naumann and Sargent (67), the potential dust exposure for each worker
task during the handling of bulk pharmaceuticals has been estimated (Table 2).
Exposure during chemical synthesis of derivatives may also result in exposure
during different work activities that may be similar to those during fermentation.
Formulation of end-products is envisaged to result in several different exposure
situations due to the diversity of products that can be prepared. However, when
ready-to-sale end-products are handled, exposure is not expected to occur from
intact packages handled following recommended procedures.
Table 2. Total dust levels in the pharmaceutical industry. Adapted from (67).
Work task Air concentration
(mg/m3)
Dumping from drums 0.9
Dumping from bags 1.2
Scooping out of drums 0.8
Filling drums from a blender 0.6
Bin transfers 0.2
Digging centrifuge 0.3
Milling 2.3
Tray dumping 2.7
Film coating 0.1
Sieving 0.8
Granulating 0.9
Compressing 0.08
Packaging 0.01
Sampling 0.01
Encapsulating 0.05
7Pharmacists are expected to be exposed during the preparation of penicillin.
solutions (i.e. mixtures and drops). Information detailed in Appendix 2 and
reference (54) shows that several penicillin solutions have to be prepared by
the pharmacists prior to use by the public. During the preparation procedure
inhalation and dermal exposure to powdered penicillins may occur. Dermal
exposure to penicillin solution cannot be ruled out. Indeed, Kobayashi details
that pharmacists have reported an increase in allergy-like symptoms that were
related to the inhalation of pharmaceutical dusts (50). Furthermore, Flink et al.
demonstrated measurable Imacillin® dust during the preparation of a penicillin
formulation conducted at Central Laboratory of the National Corporation of
Swedish Pharmacies (26).
Published data indicate that health-care-personnel (e.g. nurses and possibly
doctors) may be exposed primarily by the dermal route due to accidental spills/
leaks during preparation/administration of injectibles. Administration of other
penicillin solutions may also result in exposure. It cannot be ruled out that
exposure may occur during non-routine practices such as the manual grinding of
penicillin solids with or without liquid dispersion to facilitate the ease of admini-
stration to the elderly and other patient groups. Exposure may also occur when
preparing injectible and infusion preparations if the procedures are not strictly
conducted under "closed-system" conditions. Different potential exposure patterns
between in-clinics and out-clinics are also probable. It is also important to
consider that stress, working conditions, and technical facilities may influence
exposure to penicillins.
Veterinary workers in Nordic countries may be accidentally exposed to spills/
leaks, during preparation/administration of penicillin solutions. Exposure may
also occur during the disposal of syringes under out-clinic conditions. Frequent
exposure of veterinarians may occur during administration of "intra-mammary
penicillins" for the treatment of infected cow udders (mastitis). Respiratory,
dermal, and eye exposure to penicillin residues bound on detached animal skin
and hair may occur. It is also important to consider that the working conditions of
a veterinarian on out-clinic duties are extremely variable depending on the work
location setting (e.g.farm) and type of animals to be treated (e.g. agricultural,
reared, domestic, fishery). Because of these variables, stress is expected to
influence the potential exposure to penicillin.
Agricultural workers may be exposed to penicillins as they perform the
administration of penicillin preparations to livestock during the treatment period.
Exposure to penicillin residues bound on detached animal skin and fur may occur.
Exposure via excreta, waste cows´ milk during the withdrawal period, and other
sources cannot be ruled out.
Fishery workers may be exposed to penicillins during large scale spraying.
Exposure to aerosolised penicillins may occur by inhalation and dermal contact.
Because penicillin is routinely used in laboratories as a bacteriostate and in
some instances for research, exposure of laboratory personnel is likely.
The general public (non-occupational exposed population) is also considered
here, as occupationally exposed workers are also the general public and may be
8exposed through the use of medicines containing penicillin. In 1946, Friedlaender
pointed out that, occupational dermatitis may be more prevalent in workers
receiving topical therapies of penicillin (29). This conjecture may have also been
extended to respiratory effects because of the use of aerosolised penicillin as a
treatment. Although topical and inhalatory penicillins are no longer available it is
of interest that preparations of penicillins are available to the general public in the
powdered form. These are sold as single dose preparations intended for prepara-
tion of a solution by the patient (54). Hence, there is the possibility that inhalatory
and skin exposure may occur. It is also possible that dermal exposure of adult
workers to penicillin solutions intended for children may occur due to accidental
spills during handling of the solution and the expectorating reaction of children
unwilling to swallow the medicine. It is also important to consider that workers
are indirectly exposed via the environment to e.g. food commodities that may
contain penicillin residues: the study by Naclerio et al. (66) demonstrated that a
penicillin sensitised nurse elicited hypersensitivity symptoms on consumption of
certain foods. Aguis et al. commented that there may be evidence of allergic
sensitisation to a therapeutic substance as a result of occupational exposure to the
substance (1). Therefore, the reverse must also be considered.
Based on the above it is expected that the main routes of occupational exposure
to penicillins will be via inhalation and dermal exposure to powders, solutions,
and aerosols. However, oral exposure and exposure to penicillin vapour may
occur. Oral exposure of workers in the non-occupational situation may have to be
considered when taking medications. Thus, multiple pathways of exposure of
different populations have to be considered as different sources and portals of
entry that may contribute to exposure under different situations. It is also neces-
sary to take into account variations in exposure levels. The exposure during the
sensitisation and elicitation phases in immunologically mediated hypersensitivity
may be spatially, temporally, and quantitatively different.
In summary, the occupational groups that are potentially exposed to penicillins
include:
– workers involved in the manufacture, processing and formulation including
handling of penicillins.
– pharmacists preparing formulations of penicillins.
– health-care-personnel administering penicillins to humans and possibly
preparing formulations.
– veterinarians preparing formulations and administering penicillins to animals.
– agricultural workers using/administering penicillins in connection with animals
and exposure from animal waste and products.
– fishery workers using penicillins on fishery farms.
– laboratory workers using penicillins for research purposes.
– workers exposed to penicillins at work, via the use of medications, and in the
non-occupational environment.
95. Measurement and analysis of workplace exposure
5.1 General
Analytical methods for the detection of penicillins may be classified into two
broad groups:
– immunological and microbiological techniques which respond to groups of
penicillins but do not discriminate among them (screening methods), and
– compound-specific methods, involving chemical or physical separation of
the specific drug from other components for the detection, identification and
discrimination among different penicillins (chromatographic methods).
5.2 Screening methods
Screening test methods for the detection of penicillin residues include the classical
microbial inhibition tests, such as the Swab test, the antibiotic and sulfa test, the
inhibition tests based on colorimetry, such as the Brilliant Black reduction test,
and the immunological assays, such as the enzyme-linked immunosorbent assays
(ELISA) and the Charm test II receptor assay (10). These screening test methods
are usually sensitive to penicillin G (benzylpenicillin), with a detection capacity
down to the ng/g concentration range. They also provide fairly reliable test results,
are relatively simple, inexpensive, and require simple equipment. However, they
lack compound specificity and are, at the best, semi-quantitative, and are therefore
only suitable methods when solely qualitative information is desired, e.g.
screening for presence of penicillins.
Some other screening methods, described by British, European and US Pharma-
copoeia are Ph. Eur. ed. 2 assay, which is based on mercurimetric titration, BP 80
assay, which is based on imidazole-mercury(II) spectrometry and/or iodometric
titration and USP XXI assay scheme, which is based on a number of methods
depending on the penicillins tested for, e.g. iodometric titration, hydroxylamine-
ferric ion colorimetry. Some specific spectroscopic screening methods have also
been used (86), e.g. by labelling the penicillins with a fluoropore, such as fluore-
scamine, α-amino group containing penicillins can be detected down to 20 ng/ml.
Other traditional fluorescence derivatives, e.g. dansyl chloride, were proved to be
too unstable to be useful. Penicillins have no native distinctive UV-absorption
above 220 nm, but by employing a nucleophilic attack on the ß-lactam ring by an
imidazole or triazol, an UV-absorbing derivate is formed and can be used in an
UV-spectrometric assay for penicillins (86).
5.3 Chromatographic methods
High performance liquid chromatography (HPLC) with reversed phase columns
or ion-pair reversed phase columns have extensively been used for separation of
penicillins (10, 59). For most applications a sample preparation step is needed
prior to the HPLC analysis. The extent of sample pre-treatment depends on the
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origin of the sample and can be anything from a simple dissolution to a multi-
step extraction and pre-concentration scheme. For determination of penicillin
residues in food stuff a number of sample pre-treatment procedures have been
described (10), e.g. protein precipitation procedures, solvent extraction and pre-
concentration procedures, adsorption-elution clean-up procedures, and solid-phase
extraction procedures. Of these techniques solid-phase extractions are regarded as
state-of-the-art and offers both a simple and robust sample clean-up as well as the
possibility to obtain at least a 10-fold concentration of the analytes. Different
derivatisation techniques have been employed and may decrease the detection
limit by 5-10 times (10, 59, 86). Mass spectrometry (MS) offers specific and
selective detection of penicillins and HPLC-MS has been used for the determi-
nation of specific penicillins and their metabolites (10).
6. Toxicokinetics
Location of first hand references dealing with the toxicokinetic behaviour of
penicillins is few. However, second-hand information without details of source-
references is detailed in Wright (90) and Martindale (56). These two sources
mainly concern pharmacological studies conducted by the oral and parenteral
(intravenous and intramuscular) routes. In some cases the route of exposure is not
clearly stated. Hence, information contained in Wright (90) and Martindale (56) is
only summarised in this document and further reference to these two sources is
not made. Unless otherwise stated information presented here is for the oral and
parenteral routes. Toxicokinetic studies conducted with domestic and agricultural
animals on specific veterinarian-related questions are not considered here.
6.1 Uptake
Absorption of penicillins occurs in the stomach and duodenum. For penicillins
intended for oral administration, uptake varies from 30 to 90%. Peak levels in the
serum are reached 1 to 2 hours after administration, but the presence of food may
delay attainment of peak levels. Some penicillins are either poorly absorbed by the
oral route e.g. ureidopenicillins, or broken down in the stomach by gastric juices,
for example penicillin G. These latter two penicillins are routinely administered
by parenteral routes to obtain pharmacologically sufficient systemic concen-
trations.
With the exception of one reference, (11), published studies on the toxico-
kinetics of penicillins following inhalation exposure have not be located. In that
study, absorption of aerosolised benzylpenicillin with a mass median aerodynamic
diameter of 2.81 ± 0.08 µm and a geometric standard deviation of 2.53 ± 0.05 µm
was studied in the lungs of male Sprague-Dawley rats. Benzylpenicillin had an
absorption half-time of 20.5 minutes (11). The authors showed that in general
absorption of different drugs following inhaled aerosol administration was quite
rapid, with absorption half-times ranging from less than 1 minute to more than 30
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minutes. They also demonstrated that the water solubility and molecular weight
influenced absorption. The low rate constant for absorption of benzylpenicillin
reflects its low water solubility. However, it should be noted that the anatomy,
morphology, and physiology of the respiratory systems of rodents and humans are
very different (39).
In general, the bioavailability of penicillins will depend on their physical-
chemical characteristics. Absorption of penicillins via the lungs may be affected
by the water solubility, lipophilicity, molecular weight, physical state, and
physical size (11, 39). For instance, the particle size and water solubility of a
penicillin in the dust form will influence uptake in different regions of the
respiratory system.
A fine dust would be expected to penetrate further into the lower airway system
and more be absorbed there than for a coarser dust. Water-soluble penicillin dust
is likely to be absorbed by the upper airway system. In addition, absorption via the
gastronomical tract would also be expected to contribute to the total body burden
as a portion of the inhaled dust may be swallowed after mucociliary clearance
from the upper respiratory tract and/or nasal region. The fraction of dust orally
absorbed is thought to be greater for water insoluble penicillins. Hence, the total
body burden level of penicillin following inhalation of penicillin dusts is expected
to be a contribution of pulmonary and oral absorption.
6.2. Distribution
Penicillin binding to serum proteins varies from 15% for aminopenicillins to 97%
for dicloxacillins. Phenoxymethylpenicillin is 80% bound to protein. Approxi-
mately 95% of benzylpenicillin combines with protein through the β-lactam ring
to form the benzylpenicilloyl (BPO) group, which is referred to as the "major"
antigenic determinant (19-21, 91). Five per cent or less is referred to as the
"minor" component which consist of benzylpenicillin itself and metabolised
products including penicilloates, penilloates and possibly other products. The
serum half-time is generally short, around 30 minutes for penicillin G and 60
minutes for extended-spectrum penicillins. All penicillins distribute well into
most tissues except the prostate gland, eye, and cerebrospinal fluid. However,
penicillins distribute into cerebrospinal fluid when the meninges are inflamed. In
general, distribution depends on the molecular structure and protein binding of
penicillins. The volume of distribution of penicillins is between 12 and 19 litres.
6.3 Biotransformation
Penicillins are either not or only minimally metabolised. For example, ureido-
penicillins, which are mostly present in the serum in the free form are only
metabolised by 10%. Other non-protein bound penicillins, benzylpenicillin,
phenoxymethylpenicillin, ampicillin and amoxycillin are either not metabolised
or metabolised to products including penicilloates, penilloates and possibly other
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derivatives (19-21, 91). Phenoxymethylpenicillin is metabolised to a greater
extent than benzylpenicillin in the liver.
6.4 Excretion
Of the systemically available penicillin and penicillin derived metabolites, most
are readily and primarily excreted by the kidney through glomerular filtration and
tubular secretion. Some penicillins are excreted (20-30%) by the biliary route
e.g. cloxacillins, nafacillin, oxacillin, and the ureidopenicillins. Enterohepatic
recycling of ampicillin may occur. Apparently the excretion in bile is dependent
on the route of exposure. Renal failure will increase the systemic concentration of
penicillins, especially those that are not excreted in the bile. Except for ureido-
penicillins, other penicillins apparently exhibit linear dose-dependent clearance.
7. Mechanisms of toxicity
The adverse effects of concern are: i) bronchial hyperreactivity including asthma,
ii) allergic contact dermatitis, and, iii) systemic urticaria probably including
contact urticaria. Related effects including rhinitis, conjunctivitis and anaphylaxis
have also been observed (40). Modified intestinal microflora, possibly caused by
swallowed inhaled dust, has been reported from a single study (87).
7.1 Bronchial hyperreactivity including asthma
The following discussion is mainly based on the results detailed in this report and
the publications of Chan-Yeung (13) and Cullinan and Newman Taylor (15).
For penicillin, symptoms both of the respiratory system and the vascular system
observed in association with inhalation exposure are characteristic of Type I
hypersensitivity. Classically Type I hypersensitivity is ascribed to being asso-
ciated with an IgE-mediated mechanism (30), however, the involvement of IgE in
the mechanism of penicillin-induced effects resulting from inhalation cannot be
demonstrated. Therefore, based on the available evidence, penicillin-induced
effects associated with inhalation exposure may be mediated by a non-IgE-
mediated immunological mechanism. It is recognised that a non-immunological
mechanism e.g. due to irritation to low levels of penicillin dust may be involved in
situations where exposure to dust occurs. This mechanism may account for some
specific symptoms, or co-contribute to other observed effects. However, it is
difficult to discern the contribution of a non-immunological mechanism to the
overall symptoms.
Although little is known about the details of the non-IgE-mediated
immunological mechanism associated with penicillin-induced effects it is of
interest to consider other substances that induce their effects by a non-IgE-
mediated immunological mechanism. There are several examples of agents that
cause asthma, for instance, isocyanates, plicatic acid, colophony, styrene, and
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nickel and cobalt compounds. For isocyantes and plicatic acid pathological
changes have been studied in detail in bronchial biopsies (13) Sloughing of
epithelium, thickening of the basement membrane, and cellular infiltration
particularly of eosinophiles occurs. Increased numbers of T-cells in bronchial
mucosa, suggesting a role for T-cells, has been observed. It has also been
suggested that B-cells may be involved. However, convincing evidences for the
role of a cellular mediated mechanism are at present lacking (15). Alternatively
pharmacological mediators have been suggested to be involved in the direct
mediation of induced-effects for different substances (13, 15). These include, the
direct action of complement, the direct release of histamine from peripheral
leukocytes, release of substance P, β-adrenergic blocking action, and neural
endopeptidase inhibition. Such actions may enhance an inflammatory response.
On the basis of the available information, it is not possible to determine the
influence of predisposing factors (e.g. atopy, smoking) and cofactors (e.g. dust
exposure, infection) on penicillin-induced respiratory effects.
7.2 Allergic contact dermatitis
The mechanism of delayed dermal hypersensitivity (Type IV allergy) for peni-
cillin is based both on experiments with penicillin and on a general mechanism of
action (41). The mechanism and reaction are considered to occur in two stages:
sensitisation and elicitation.
Sensitisation produces a population of memory T-cells and takes about
10-14 days in humans. In brief, once penicillin is absorbed by the skin, the
relatively low molecular weight hapten combines with protein to form a protein-
hapten conjugate. This is internalised by epidermal Langerhans’ cells, which
subsequently leave the dermis and migrate as veiled cells, via efferent lymphatics,
to the lymph nodes where processed hapten-protein conjugate complexes (in
association with MHC class II molecules) are presented to CD4+
 
lymphocytes,
producing a population of memory CD4+ T-cells. The subsequent elicitation phase
involves recruitment of CD4+
 
lymphocytes and monocytes. Re-exposure to the
antigen results in binding to Langerhans’ cells, which present the hapten-carrier
complex to memory CD4+ T-cells. These cells are activated to release IFN-γ,
which activates keratinocytes to release proinflammatory cytokines. Degranula-
tion and cytokine release by mast cells follows after contact with allergen.
Macrophages invade the dermis and epidermis by 48 hours, resulting in allergic
contact dermatitis.
7.3 Urticaria
Based on the available information it seems that systemically administered
penicillin induces urticaria. However, contact urticaria may also be involved, as it
is difficult to discern the type of exposure/absorption involved. Systemic urticaria
may be associated with anaphylactic symptoms, such as wheezing, dysponea,
syncope, abdominal pain, and vomiting. Immediate urticaria and angioedema are
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associated with systemic exposure to all penicillins given as drugs to patients (90).
Contact urticaria may be of immunological origin involving IgE-mediated hyper-
sensitivity, or of non-immunological origin (40).
7.4 Cross-reactivity
Immunological cross-reactivity is high between penicillins and carbapems,
cephalosporins and monobactams (64). Because the hypersensitivity is related to
the basic penicillin structure, individuals who are allergic to benzylpenicillin must
be assumed to be allergic to all penicillins; sensitised patients may also react to
the cephalosporins and other β-lactam antibiotics (56). Cross-reactivity among
synthetic and natural penicillins is due to their common 6-aminopenicillanic acid
nucleus and sensitising groups (90).
7.5 Vulnerability
Penicillin-induced hypersensitivity is likely to have multi-factorial causation,
involving individual susceptibility (genetic or acquired), penicillin exposure
pattern (duration, intensity, frequency), physical-chemical properties of the
penicillins, and physical state and health status of man (42, 91).
8. Effects in animals
8.1 Sensitisation
Published reports on animals, studying the effects of penicillin by inhalation
exposure have not been located and only a few studies by the dermal route have
been found.
Levine studied the dermal sensitivity potential of penicillin G on the shaved
skin of male albino guinea pigs (52). The animals were sensitised with penicillin
G by six percutaneous applications of 0.1 M solution of crystalline potassium
penicillin G (KPG; 99% pure) or D-penicillamine⋅HCl, or D-benzylpenicillenic
acid, or monosodium-D-α-benzylpenicilloate, or 2-benzyl-4-sodium hydroxy-
methylene-(5)-oxazolone, or benzylpenilloaldehyde in a solvent composed of 95%
ethanol, methylcellulose and Tween 80 (ECT; 45:45:10 v/v). A freshly prepared
solution was used on each application of 0.05 ml spread onto a 2 cm circular area
on the dorsal skin surface clipped free of hair. Applications to the same area of
skin were made 3 times a week for 14 days. After 2 weeks the animals were
patched tested for hypersensitivity with 0.1 M KPG in ECT solvent. Before
elicitation the hair of the dorsal skin surface was carefully clipped. 24 hours later,
0.04 ml of the test substance was applied to the skin. It was not detailed if the
applied test material was occluded for the exposure period. Reactions were
recorded 48 hours later. As shown in Table 3, challenge with KPG and derivative
gave a positive skin reaction.
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Table 3. Percentage skin sensitisation in animals challenged with crystalline potassium
penicillin G (52).
Sensitiser No. animals
reacting/total
Percentage
sensitised
Potassium penicillin G 30/60 50
D-Penicillamine⋅HCl 36/41 88
D-Benzylpenicillenic acid 17/20 85
Monosodium-D-α-benzylpenicilloate 5/10 50
2-Benzyl-4-sodium hydroxymethylene-(5)-oxazolone 5/10 50
Benzylpenilloaldehyde 9/10 90
The skin-sensitising potential of penicillin G has also been studied in the guinea
pig maximisation test, a predictive test recommended in the Organisation for
Economic Co-operation and Development (OECD) test guideline 406 for skin
sensitisation (69). In four studies (6, 31, 51, 55), penicillin G was classified as an
extreme allergen (Grade V, 81-100% sensitised animals) and in one study (58), as
a strong allergen (Grade IV, 65-80% sensitised animals) according to the
Magnusson and Kligman classification (55). In the study by Kristofferson et al.
cloxacillin and bacampicillin were also tested and both were classified as grade V
allergens (51). For details, see Table 4. Extensive cross-reactivity was shown
Table 4. Guinea pig maximisation test conditions and results with penicillins.
Substance Animal
strain
Number
(sex) of
animals
Induction
concentration
Challange
concentration
Response
% positive
animals
Reference
Penicillin G Hartly 20 (f) 3% id
5% pet ec
10% pet 100 (55)
Penicillin G Pirbright 20
(10m,10f)
0.3% id,
5% pet ec
10% pet 74 (58)
Penicillin G –a 27 (m) 0.63-2.5% idb
25% eth ec
5% eth 90b (51)
Penicillin G Dunkin-
Hartly
20 (f) 25% eth id
25% eth ec
10% eth 90-100 (31)
Penicillin G Dunkin-
Hartly
20 (sex not
    specified)
1.0% id
10% ec
5.0% phys 100 (6)
Cloxacillin – 16 (m) 0.32-1.25% idb
25% eth ec
5% eth 100b (51)
Bacampicillin – 26 (m) 0.16-0.63% idb
25% eth ec
5% eth 100b (51)
Abbreviations: ec, epicutaneous; eth, ethanol; f, female; id, intradermal; m, male; pet, petrolatum;
phys, 0.9% NaCl in H2O.
a  not given.
b
 Induction were performed, besides the ec treatment, with 3 different id concentrations. No
difference in sensitisation rate could be detected and only the combined results were given.
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between the penicillins in penicillin G and bacampicillin sensitised animals
whereas the cloxacillin sensitised animals showed a more restricted reactivity
(51).
The contact sensitising potential of penicillin G has also been tested in the local
lymph node assay (6, 82). The method has been recommended in the OECD
guideline 406 as a screening test for assessing skin sensitisation potential. In the
case of a positive response a substance may be designated as a potential sensitiser
and in the case of a negative result a guinea pig test must be conducted (69). The
local lymph node assay utilises mice as the study animal and, in distinction to
the guinea pig tests, it measures the response in the induction phase as cell proli-
feration ([3H]thymidine incorporation) in auricular lymph nodes after topical
application of the test substance to the dorsum of the ears (43).
Penicillin G was dissolved in dimethylsulphoxide and tested in the local lymph
node assay at three concentrations: 10, 25, and 50% (w/v). CBA/Ca mice were
used. A stimulation index (SI) was calculated for each group, i.e. the test group
proliferation value / control group (vehicle treated) proliferation value, and were
1.5, 3.8, and 8.9, for the three concentrations, respectively (6).
A chemical is classified as a potential sensitiser in the local lymph node assay
if two criteria are fulfilled: i) At least one concentration of the test chemical
induces a SI of a threefold or greater value than that of the vehicle control; ii) the
result must not be incompatible with a biological dose-response (43). Penicillin G
would thus be classified as a potential sensitiser according to the local lymph node
assay.
It has been proposed (53) that the relative contact sensitising potential of a
chemical can be ranked in the local lymph node assay by the EC3-value (estimated
concentration for SI = 3) obtained for that chemical. The EC3-value for penicillin
G calculated from Basketter and Scholes (6) is 20% (0.56 mol/dm3(M)). EC3-
values for penicillin G has also been reported by Kimber et al. (44) in an inter-
laboratory evaluation of the local lymph node assay, and were estimated to be
31.3, 16.1, 46.4, 46.5, and 41.1% for each of the five participating laboratories.
These values are to be compared with EC3-values of other allergens, e.g. 0.0765%
(0.00383 M) for 2,4-dinitrochlorobenzene (5), 6.85-9.63% (0.317-0.445 M) for
hexyl cinnamic aldehyde (33), and 5.8-14.5% (0.353-0.883 M) for eugenol (53).
The first substance has a high sensitising potential whereas the two latter are
considered to have a more moderate skin sensitising potential. Hence, based on
this system penicillin would be ranked as even as a weaker sensitiser. However,
the specificity of the local lymph node assay has been questioned and the assay
requires further validation (2, 65).
In another method that utilises mice as the study animal and measures the
cellularity in the popliteal lymph nodes, the mouse popliteal lymph node assay,
penicillin G was tested in two inbred mouse strains (BALB/c and A/J) and one
outbred strain (ICR) by four different laboratories (82). Two inbred mouse strains
(BALB/c and A/J) and one outbred strain (ICR) were subcutaneously injected
with saline solutions containing penicillin G (1.25, 2.5 and 5 mg/mouse) into one
hind footpad and saline only was injected into the contralateral footpad. Popliteal
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lymph node cellularity indices were determined on day 7. An approximate dose-
dependent response was observed in all three strains. Popliteal lymph node
responses in A/J, BALB/c and ICR mouse strains were high, intermediate and
low, respectively. Dose-dependent popliteal lymph node responsiveness was
almost comparable in four laboratories, although popliteal lymph node cellularity
indices ranged from 1.5 to 3.2 for the moderate and maximum penicillin dose.
9. Observations in man
9.1 Occupational exposure
9.1.1 General
For convenience effects information is reported for different work categories
separately. The studies detailed are cross-sectional or a series of case reports in
the workplace. Analytical epidemiological studies have not been performed.
Exposure levels are rarely reported, these studies are cited in this document.
Reports on factory workers concern exposure to penicillin dusts and mainly
effects on the skin and respiratory system. One report details hypersensitivity
pneumonitis in a single person. The information contained in this section is
directly relevant for identifying a critical effect(s), dose-response (effect)-
relationships, and relevant occupational exposure scenarios. These points are
further discussed after this section.
9.1.2 Factory workers
In a non-peer reviewed report by Hanke and Patnode (32), they evaluated asth-
matic symptoms in employees working with powdered and granulated penicillin.
A combined industrial hygiene and medical-epidemiological evaluation of 36
penicillin workers (26 females and 10 males) and a comparison group (non-
penicillin group) of 27 employees (23 females and 4 males) was conducted at a
pharmaceutical company in USA. Personal breathing-zone environmental samples
determined that the non-penicillin group had an average total dust exposure of
0.30 mg/m3 (0.20-0.74 mg/m3). Among workers exposed to penicillin, the
following average levels of exposure were found for three penicillin subgroups:
5.97 mg/m3 (range 2.48-12.47 mg/m3; "high exposure") for production workers;
0.50 mg/m3 (range 0.08-1.48 mg/m3; "intermediate exposure") for packers in
quality control; and, 0.29 mg/m3 (range 0.12-0.45 mg/m3; "low exposure") non-
production workers. The penicillin group (combined subgroups) compared with
the non-penicillin group was characterised by an excess prevalence of attacks of
shortness of breath (15/36; 42% cf. 2/27; 7%). Increased prevalence of three
additional asthma-like symptoms was demonstrated in females of the penicillin
group: chronic cough (13/26; 50% cf. 2/23; 9%), wheezing (14/26; 54% cf. 2/23;
9%), and breathlessness (9/26; 35% cf. 1/23; 4%). No dose-response relationship
was found between asthma-like symptoms and exposure of subgroups to penicillin
dust. The authors could not conclude unequivocally that occupational asthma due
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to penicillin dust did occur in the plant. They also proposed that the atopic status
of a worker (presence of hay fever) was a predisposing factor for development of
asthma.
Shmunes and co-workers studied 169 employees in a synthetic penicillin plant
in a US National Institute for Occupational Safety and Health (NIOSH) study to
correlate immunology reactions, allergic symptomatology and dustiness of the
work area (83). Grouping of workers by range of dustiness in the workroom air
was conducted. Air samples were collected on Millipore filters, Type AA, 0.8 µm
pore size. The main groups were: Group A, 62 workers exposed to below 0.1
mg/m3; B, 49 workers exposed to 0.1-9.9 mg/m3; C, 42 workers exposed to 10-
263 mg/m3; and, D, 16 workers exposed episodically. A personal and/or family
history of atopy was present in 49/169 workers. Only symptoms that appeared
during employment were considered. Comparison of groups B and C separately
with A showed statistically significant (P = <0.01) positive correlations among
dust concentrations, allergic symptoms, and penicillin specific antibodies. Of 112
symptoms expressed by 67 workers, the most frequent target organs represented
by the symptoms (greater than five elicitations) were the skin, upper respiratory
tract, and eyes. Hemagglutinating anti-penicillin antibodies were detected in the
sera of 73 employees. There was a statistically significant relationship between
the presence or absence of antibodies (IgG and IgM) and the presence or absence
of symptomology. Respiratory symptoms (wheezing) were found in 2% of those
examined. The study indicates that employees exposed to ≥0.1 mg/m3 penicillin
can induce allergic symptoms.
In 1974, Davies et al., reported on four workers in UK who developed respira-
tory complaints after working in an ampicillin production factory for up to 12
years (17). Three workers developed typical delayed-onset occupational asthma
and rhinitis after 2 years of employment, while the fourth developed symptoms of
cough and dyspnea suggesting occupational asthma. These patients were investi-
gated by routine skin testing of ampicillin and related substances, as well as by
bronchial and oral provocation studies. Skin tests were negative to ampicillin,
benzylpenicillin, and 6-amino penicillanic acid. Three of the four patients had
delayed and prolonged asthma and eosinophilia on inhalation challenge. All three
patients reacted to commercial and purified ampicillin, while one reacted to
purified 6-amino penicillanic acid and another to benzylpenicillin. The authors
commented that this pattern of response indicated that impurities in the antibiotic
preparations were unlikely to be the compounds responsible for the decline in
forced expiratory volume in one second (FEV1). Furthermore, oral antibiotic
challenges confirmed systemic hyperresponsiveness in two of the three positive
reactors.
A number of case reports with little information on exposure conditions are
summarised in Table 5.
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9.1.3 Health-care-personnel (medical workers), veterinarians, and laboratory
workers
Case reports on health-care personnel, veterinarians, and laboratory workers with
little or no information on exposure are summarised in Table 6.
9.1.4 Patients
Data on patients is briefly reviewed in this document as the results are relevant for
dermal and inhalation exposure to penicillin.
According to Martindale the most common adverse effects of penicillins used
by patients are hypersensitivity reactions, especially skin rashes and occasionally
anaphylaxis, which has sometimes been fatal (56).
In a comprehensive review written by DeSwarte, it is reported that bronchial
asthma has been shown in patients treated with aerosolised penicillin (19). Also
contact dermatitis (Type IV reaction) due to the sensitising properties of topically
applied penicillin has been demonstrated in patients (see also Friedlaender et al.
(29). These treatments by the inhalation and dermal routes have been discon-
tinued. According to DeSwarte, anaphylactic and urticarial reactions, typical of
Type I reactions, have been documented to be caused by topical application. The
review does not, however, cite the source of this information. Fisher also refers to
aerosol and topically applied penicillin as inducing allergy without citing the
source (24).
9.2 Experimental exposure
The contact sensitising potential of penicillin G has been experimentally estimated
in humans in the human maximisation test (48) and the “reduced maximisation
test” (47). The results are summarised in Table 7.
A panel of 24 healthy male prisoners, aged 18-50 years (90% of the subjects
were black) were used as experimental subjects. For induction exposure a 3.8 x
3.8 cm patch containing 1.0 ml of 25% (w/w) penicillin G in petrolatum were
applied for 48 hours on the forearm or calf under occlusion for 48 hours. The
induction site was pre-treated with sodium lauryl sulphate for 24 hours to induce
a moderate inflammatory reaction. This sequence of alternating 24 hours irritant
and 48 hours penicillin patches were repeated for a total of five exposures of each
(48). The rest period between induction and challenge was not stated but was
probably two weeks (49). For challenge, an occlusive patch (2.5 x 2.5 cm)
containing 0.4 ml of 10% (w/w) penicillin in petrolatum were applied to the lower
back for 48 hours, after pre-treatment of the test site for one hour with sodium
laruyl sulphate. The challenge reaction was read immediately after removal of
the patch and again in another two days. An evident erythema, clearly more
inflammatory than a control patch consisting of petrolatum, was the minimum
requirement to be considered as a positive response. A sensitisation rate of 16/24
(67%) was found, which classifies penicillin G as a strong (Grade IV, 56-80%
sensitisation rate) sensitiser in this test (48). The experiment was repeated on three
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Table 7. Summary of human maximisation test and "reduced maximisation test" results
with penicillin G (47, 48). For description of the methods see the text.
                     Induction          Sensitisation rate
Experiment
No.
Concentration
(%, w/w)
No. of patches
(exposures)
Positive reactions/
No. subjects
      %
1 25    5 16/24 67
2 25    5 16/23 70
3 25    5 12/23 52
4 25    5 13/25 52
5 0.2    5 2/22   9
1.0    5 4/22 18
5.0    5 7/25 28
10    5 11/25 44
25    5 16/25 64
6 10    3 1/25   4
10    5 5/25 20
10  10 10/21 48
10  15 16/21 76
7a 0.1 1 x 5 0/23   0
0.1 2 x 5 2/22   9
0.1 3 x 5 6/24 25
8 0.1  15           –b   –
a Induction was conducted with one to three sensitisation courses, each consisting of five
exposures. The time period between courses was not given.
b not given.
occasions and sensitisation rates of 16/23 (70%), 12/23 (52%), and 13/25 (52%)
were obtained, respectively. The two latter results with penicillin G are classi-
fiable as a moderate sensitiser (Grade III, 32-52% sensitisation rate). The author
concludes that the classification of penicillin G as a strong contact sensitiser
corresponds well with clinical experience and that sensitisation rating may have
been higher if only Caucasian subjects had been tested (48).
In an additional report, a modified human maximisation test, "reduced maxi-
misation test", was used (47). The testing procedure was exactly the same as
described above except that different concentrations, non-maximal, were used for
induction. Induction exposures to 0.2, 1.0, 5.0, 10, and 25% (w/w) penicillin G in
petrolatum sensitised 9% (2/22), 18% (4/22), 28% (7/25), 44% (11/25), and 76%
(16/21) of the tested subjects, respectively (47).
The influence of the number of exposures during the induction procedure on
sensitisation rate was also investigated (47). The same site on one extremity was
exposed for a maximum of five per site; each course of five exposures was
conducted on a new fixed site on the same extremity. A 10% concentration of
penicillin G was used as induction concentration and 3, 5, 10, and 15 exposures
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sensitised 4% (1/25), 20% (5/25), 48% (10/21), and 64% (16/25) of the tested
subjects, respectively (47).
Sensitisation rates with threshold induction concentrations of penicillin G,
0.1%, were tested with three sensitisation courses, each consisting of five
exposures (47). Each course was applied to the same site on one extremity; a new
site was used for each five exposure courses (the time interval between courses
were not given). One, two, and three sensitisation course sensitised 0 (0/23),
9 (2/22), and 25% (6/25), respectively. In the same article the author states (47)
that they have not succeeded in producing sensitisation with 15 exposures to
0.1% penicillin G (see Table 7, experiment 7 and 8). The difference in these two
experiments is not clear except that in experiment 7 each course of five induction
exposures seems to be more clustered.
10. Dose-effect and dose-response relationship
Based on the available information it is difficult to establish a dose-effect
relationship.
Shmunes et al. reported a significantly higher incidence of allergic symptoms in
workers exposed to 0.1-9.9 mg/m3 as compared to below 0.1 mg/m3 (83).
In a non-peer reviewed study conducted by Hanke & Patnode (32), the exces-
sive prevalence of asthma-like respiratory symptoms was observed in penicillin-
exposed workers to a total dust concentration of 0.29 mg/m3 (0.12-0.45 mg/m3).
However, a dose-response relationship was not demonstrated between asthma-like
symptoms and exposure to penicillin dust.
In both theses studies the effects have been correlated with the total dust level,
assuming that all dust emanated from penicillin. Such an assumption may be valid
in some cases, principally when the only dust source is dry penicillins or dry drug
formulations with known penicillin content. However, in most other cases such an
assumption would lead to a significant error in the determination of the airborne
penicillin concentrations and does, therefore, not represent an adequate approach.
A semi-quantitative relationship between the inhibition of penicillin-sensitive
bacteria, and respiratory and dermal symptoms has been demonstrated (62);
however, this information is difficult to use in an exposure-response analysis
unless the degree of inhibition of bacterial growth is standardised.
Qualitative descriptions of dustiness and association with effects of penicillin
cannot be used in this document (74).
11. Previous evaluations by (inter)national bodies
The International Agency for Research on Cancer (IARC) conducted an
evaluation of carcinogenic risks to humans of ampicillin (trihydrate and sodium
salt) considering oral and parenteral routes of administration (38). The overall
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evaluation was that "Ampicillin is not classifiable as to its carcinogenicity to
humans (Group 3)".
European Centre for Ecotoxicology and Toxicology for Chemicals (ECETOC),
stated that penicillin G [calcium and potassium salts CAS No. 973-53-5 and 113-
98-4] are considered as human and animal skin sensitisers (22).
12. Evaluation of human health risks
12.1 Assessment of health risks
For workers, there is evidence that exposure in their working environment can
cause asthma. Several authors have described cases of workers employed in the
manufacture of synthetic penicillin antibiotics developing attacks of shortness of
breath and wheezing (e.g. (32)).
In addition, penicillin aerosols have been withdrawn for the treatment of
patients because of their sensitising properties.
There is convincing evidence that penicillin causes delayed skin hypersensi-
tivity due to exposure to both penicillin dusts and solutions. This has been shown
in the majority of the occupationally related reports detailed in chapter 9
"Observations in Man".
Urticaria has been observed in several studies. The available information both
on occupational and non-occupational exposure routes show that systemic-
dependent urticaria and probably contact-dependent urticaria are critical effects.
Hoyos et al. described the unusual co-existence of hypersensitivity pneumonitis
(18). Penicillin-induced hypersensitivity pneumonitis has been rarely described
and the authors comment that the cause-effect association has never been
established to their knowledge (89). Hence, this effect cannot at present be
regarded as representative.
Concerning the single report on modified human intestinal microflora (87), this
would probably occur due to oral exposure of swallowed inhaled dust. Because
this study is poorly reported and it does not seem to be representative, this study
cannot be considered to be of adequate quality to justify this as an adverse effect.
Thus, it is concluded that three adverse effects are convincingly substantiated to
be health risks for workers occupationally exposed to penicillin dusts and
solutions:
– bronchial hypersensitivity including asthma by a non-IgE-dependent
mechanism.
– allergic contact dermatitis (Type IV).
– systemic urticaria probably including contact urticaria.
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12.2 Groups at extra risk
Because immunological cross-reactivity is high between penicillins and
carbapems, cephalosporins and monobactams (64), workers that exhibit cross-
reactivity should be regarded as a group at extra risk.
Based on available data, it is not possible to determine whether atopic
individuals in general are more sensitive to the adverse effects of penicillin.
12.3 Scientific basis for an occupational exposure limit
The critical adverse effect considered for the basis of an occupational exposure
limit is the development of occupational asthma as reported in the non-peer
reviewed report by Hanke and Patnode (32). In this study, an excessive prevalence
of asthma-like symptoms was observed in penicillin-exposed workers with a total
dust exposure of 0.29 mg/m3 (0.12-0.45 mg/m3).
13. Research needs
The following information is required to improve this risk assessment of penicillin
on human health and support risk management considerations.
– Development of robust and simple sampling and analytical methods for
airborne penicillins in workplace air.
– Collection of exposure information both environmental and biological (effect)
monitoring data and/or better characterise work activities that may result in
exposure to penicillin for different occupational groups. It is recognised that
monitoring and industrial field survey information may be available to
regulatory authorities and it is therefore encouraged that this information be
collated and published.
– Characterise the mechanism of penicillin-induced non-IgE-mediated
respiratory hypersensitivity/-reactivity.
– Development of a reliable and convenient test system to determine the potential
for respiratory and dermal hypersensitivity. This is considered especially
relevant for penicillin-induced non-IgE-dependent respiratory hyperreactivity.
This test may then be used as a biological effect monitoring test for
surveillance in the occupational setting.
– Need to conduct a longitudinal epidemiological study to determine the
association between exposure to penicillin and the incidence and prevalence of
dermal and respiratory effects.
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14. Summary
Moore GA, Nygren O. The Nordic Expert Group for Criteria Documentation of
Health Risks from Chemicals. 134. Penicillins. Arbete och Hälsa 2004;6:1-57.
This document reviews the health risks from occupational exposure to penicillins.
Penicillins are produced in large amounts for use as antibiotics. Few quantitative
data on occupational exposure are available, however, the potential exposure to
penicillins is identified among several worker groups.
The adverse health effects associated with inhalatory and dermal exposure to
penicillins are:
– bronchial hypersensitivity including asthma
– allergic contact dermatitis and,
– systemic urticaria probably including contact urticaria.
In a non peer-reviewed report, workers in the penicillin manufacturing industry
exposed to a total dust concentration of 0.29 mg/m3 (0.12-0.45 mg/m3) had an
excess prevalence of asthma-like symptoms.
Keywords: allergy, exposure levels, health effects, occupational exposure limit,
penicillin, review, risk assessment, sensitisation.
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15. Summary in Swedish
Moore GA, Nygren O. The Nordic Expert Group for Criteria Documentation of
Health Risks from Chemicals. 134. Penicillins. Arbete och Hälsa 2004;6:1-57.
Detta dokument behandlar hälsorisker vid yrkesmässig exponering för
penicilliner. Penicilliner produceras i stora kvantiteter för användning som
antibiotika. Få kvantitativa uppgifter om exponeringsnivåer föreligger men
flera yrkeskategorier med möjlig exponering är identifierade.
De kritiska effekter associerade med inhalation och hudexponering för penicilliner
är:
– bronkiell hypersensibilisering och astma,
– allergiskt kontakteksem,
– systemisk urtikaria troligen inkluderande kontakturtikaria.
I en rapport (ej publicerad i en peer-review-granskad tidskrift) uppvisade arbetare
inom penicillin tillverkningsindustrin exponerade för en total dammhalt på 0.29
mg/m3 (0.12-0.45 mg/m3) en ökad förekomst av astma-liknande symptom.
Nyckelord: allergi, exponeringsnivåer, hygieniska gränsvärden, hälsoeffekter,
penicillin, riskbedömning, sensibilisering, översikt
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17. Data bases used in search for literature
In the search for literature the following data bases were used:
MEDLINE
NIOSHTIC
TOXLINE
Last search was performed in January 2000.
Submitted for publication May 26, 2004.
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Appendix 1
Chemical and physical properties of penicillins used in Sweden.
CAS No. 54-35-3
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-[(phenylacetyl)amino]- [2S-(2a,5a,6b)]-, compd. with 2-(diethyl-
amino)ethyl 4-aminobenzoate (1:1)
Other chemical index
names
Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester, mono[[2S-
(2a,5a,6b)]-3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate] (9CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-(2-phenylacetamido)-, compd. with 2-(diethylamino)ethyl p-
aminobenzoate (1:1) (8CI)
Synonyms/Trade
names
Benzylpenicillin Novocaine; Benzylpenicillin novocaine salt;
Benzylpenicillin procaine; Benzylpenicillin procaine salt;
Benzylpenicillinum Procainum; Depocillin; Duphapen; Hostacillin;
Hydracillin; Jenacillin O; Micro-Pen; Nopcaine; Penicillin G Procaine;
Penzal N 300; Procaine Benzylpenicillin; Procaine benzylpenicillin salt;
Procaine benzylpenicillinate; Procaine Benzylpenicillinum; Procaine
Penicillin; Procaine Penicillin G; Retardillin; Vetspen; Vitablend
Molecular formula C16H18N2O4S.C13H20N2O2
Molecular weight 571
Structural formula
N
O
N
H
CH3S
CH3
CO2H
C
O
CH2 CO2 CH2 N
CH2
CH2
H2N
CH2
CH3
CH3
Physical state at 25°C Solid white crystalline powder
Solubility 1 in 250 (water)
1 in 30 (ethanol)
1 in 60 (chloroform)
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 69-52-3
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(amino-
phenylacetyl)amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-
[2a,5a,6b (S*)]]-
Other chemcial index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(2-amino-2-
phenylacetamido)-3,3-dimethyl-7-oxo-, monosodium salt, D-(-)- (8CI)
Synonyms/Trade
names
Alpen-N; Amcill-S; D(-)-alpha-Aminobenzylpenicillin sodium salt;
Ampicillin-Na; Ampicillinnatrium; Ampicillinum Natricum; Ampicillin
sodium; Ampicillin sodium salt; Anhypen; Binotal sodium; Britapen
injection; Citteral; D-.alpha.-Aminobenzylpenicillin sodium salt;
Domicillin; Monosodium ampicillin; Omnipen-N; PEN A/N; Penbritin-
S; Penialmen; Polycillin-N; Principen/N; Sodium 6-[D-.alpha.-amino-
phenylacetamido]penicillanoate; Sodium D-(-)-alpha-aminobenzyl-
penicillin; Sodium D-.alpha.-aminobenzylpenicillanate; Sodium
amipicillin; Sodium binotal; Sodium P-50
Molecular formula C16H19N3O4S.Na
Molecular weight 372
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
O
CH
NH2 Na
+
-
Physical state at 25°C Solid off white powder
Melting point °C 205 with decomposition
Solubility 1 in 2 (water)
1 in 50 (ethane)
Colloidal dispersion which gelts on standing is formed in ethanol
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 69-57-8
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-[(phenylacetyl)amino]- [2S-(2a,5a,6b)]-, monosodium salt
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-(2-phenylacetamido)-, monosodium salt (8CI)
Synonyms/Trade
names
American Penicillin; Benzylpenicillinic Acid Sodium Salt;
Benzylpenicillin; Benzylpenicillin natr.; Benzylpenicillin Sodium;
Benzylpenicillin Sodium Salt; Crystalline penicillin G; Crystapen;
Monosodium benzylpenicillin; Mycofarm; Novocillin; Pen-A-Brasive;
Penicillin-G, Monosodium Salt; Penicillin G; Penicillin G, Sodium;
Penicillin G, Sodium Salt; Penilaryn; Sodium Benzylpenicillin; Sodium
Benzylpenicillin G; Sodium 6-(phenylacetamido)penicillanate; Sodium
Benzylpenicillinate; Sodium Penicillin; Sodium Penicillin G; Sodium
Penicillin II; Veticillin
Molecular formula C16H18N2O4S.Na
Molecular Weight 357
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
O
CH2
-
Na+
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 132-98-9
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-[(2-phenoxyacetyl)amino]-, monopotassium salt, [2S- (2a, 5a, 6b)]
Other CA index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-(2-phenoxyacetamido)-, monopotassium salt (8CI);
Synonyms/Trade
names
Abbopen; Antibiocin; Apsin VK; Arcacil; Arcasin; Beromycin;
Beromycin 400; Beromycin (penicillin); Betapen-VK; Calciopen;
Calciopen K; Cliacil; Compocillin-VK; Distakaps V-K; Distaquaine V-K;
Dowpen V-K; DqV-K; Fenocin; Fenoxypen; Isocillin; Icipen; Ispenoral;
Kavepenin; Kåvepenin; Ledercillin VK; Megacillin oral; Oracil-VK;
Orapen; Ospeneff; Pedipen; Penagen; Pencompren; Penicillin potassium
phenoxymethyl; Penicillin V potassium; Penicillin V potassium salt;
Penicillin VK;Pen-Vee K; Pen-Vee K powder; PenVikal; Pfizerpen VK;
D-alpha-phenoxymethylpenicillinate K salt; Phenoxymethylpenicillin
potassium; Phenoxymethylpenicillin potassium salt; Potassium penicillin
V; Potassium penicillin V salt; Potassium phenoxymethylpenicillin;
Potassium phenoxymethylpenicillinate; PVK; Primcillin; Qidpen VK;
Robicillin VK; Rocillin-VK; Roscopenin; SK-penicillin VK; Stabillin VK
syrup 125; Stabillin VK syrup 62.5; Sumapen VK; Suspen; Tikacillin; V-
Cil-K; Uticillin VK (V-Cillin K, Veetids, Vepen)
Molecular formula C16H18N2O5S.K
Molecular weight 389
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
O
CH2O
-
K+
Physical state at 25°C Solid white crystalline powder
Melting point °C 263-265 with decomposition
Partition coefficient
(Log P(o/w))
1.95 (37°C)*, unionised species
-1.65 (37°C)*, ionised species
Solubility 1 in 1.5 (water)
1 in 150 (ethanol)
practically insoluble in chloroform, ether and insoluble in acetone
Remarks *Calculated values, (Tsuji et al)
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 642-78-4
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2-
chlorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-
oxo-, monosodium salt, [2S-(2a,5a,6b)]-
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[3-(o-chloro-
phenyl)-5-methyl-4-isoxazolecarboxamido]-3,3-dimethyl-7-oxo-, mono-
sodium salt (8CI)
Synonyms/Trade
names
Alclox; Anaclosil; Ankerbin; Apo-Cloxi; Austrastaph; Bactopen; BRL
1621 sodium salt; Clocillin; Cloxacillin sodium; Cloxacillin sodium salt;
Cloxapen; Cloxin; Cloxypen; Ekvacillin; Gelstaph; Landerclox;
Monosodium cloxacillin; Novocloxin; Nu-Cloxi; Orbénine; Orbenin;
Orbenin sodium; Prevencilina P; Prostaphilin A; Prostaphlin A; Sodium
cloxacillin; Sodium orbenin; Sodium syntarpen; Staphybiotic; Syntarpen
sodium salt; Tegopen
Molecular formula C19H18ClN3O5S.Na
Molecular weight 459
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
OCl
CH3O
N
-
Na+
Physical state at 25°C Solid white almost white powder
Solubility 1 in 2.5 (water)
1 in 30 (ethanol)
Remarks Multi-ingredient preparations: Ampiclox, Amplium
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 751-84-8
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-[(phenylacetyl)amino]- [2S-(2a,5a,6b)]-, compd. with N-(phenyl-
methyl)benzeneethanamine (1:1)
Other chemical index
names
CN   Benzeneethanamine, N-(phenylmethyl)-, [2S-(2a,5a,6b)]-3,3-
dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]
heptane-2-carboxylate (9CI)
Penicillin G, N-benzylphenethylamine salt (6CI)
Phenethylamine, N-benzyl-, 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
Synonyms/Trade
names
Benapen; Benetacil; Benethamine penicillin; Benethamine penicillin G;
Benetolin; Benzylpenicillin N-benzyl-2-phenylethylamine salt; Benzyl-
penicillinic acid N-benzyl-.beta.-phenylethylamine salt; Betapen; N-Ben-
zyl-2-phenylethylamine salt of benzylpenicillin; N-Benzylphenethylamine
benzylpenicillin salt; Penicillin G benethamine
Molecular formula C16H18N2O4S.C15H17N
Molecular weight 546
Structural formula
N
O
N
H
CH3S
CH3
CO2H
C
O
CH2
N
H
CH2CH2 CH2
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 1538-09-6
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-[(phenylacetyl)amino]- [2S-(2a,5a,6b)]-, compd. with N,N'-
bis(phenylmethyl)-1,2-ethanediamine (2:1)
Other chemical index
names
1,2-Ethanediamine, N,N'-bis(phenylmethyl)-, bis[[2S-(2.a,5a,6b)]-3,3-
dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabi-
cyclo[3.2.0]heptane-2-carboxylate] (9CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-(2-phenylacetamido)-, compd. with N,N'-dibenzylethylenediamine
(2:1) (8CI)
Ethylenediamine, N,N'-dibenzyl-, bis[3,3-dimethyl-7-oxo-6-(2- phenyl-
acetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate] (8CI)
Penicillin G, N,N'-dibenzylethylenediamine salt (6CI)
Synonyms/Trade
names
Ampicillin N,N'-dibenzylethylenediamine salt; Beacillin; Benzacillin;
Benzapen; Benzathine Penicillin; Benzathine Benzylpenicillin; Benzathini
Benzylpenicillinum; Benzathine penicillin G; Benzethacil;
Benzilpenicillina Benzatinica; Benzylpencillin dibenzylethylenediamine
salt; Benzylpenicillin benzathine; Benzylpenicillin N,N'-dibenzyl-
ethylenediamine salt; Benzylpenicillinum Benzathinum; Bica-penicillin;
Bicillin; Bicillin 1; Bicillin I; Cepacilina; Cillenta; Debecillin;
Debecylina; Diamine penicillin; Dibencil; Dibencillin; Dibenzylethylene-
diamine dipenicillin G; Duropenin; Ethylenediamine, N,N'-dibenzyl-,
compd. with penicillin G (1:2); Extencilline; Extenicilline; Lentopenil;
Longacilina; Longicil; Megacillin suspension; Moldamin; N,N'-Di-
benzylethylenediamine bis[benzyl penicillin]; N,N'-Dibenzylethylene-
diamine salt of benzylpenicillin; Neolin; Pen-Di-Ben; Penadur; Pendepon;
Penditan; Penduran; Penicillin G Benzathine; Penicillin G, compd. with
N,N'-dibenzylethylenediamine (2:1); Penidural; Penidure; Penzaethinum
G.NN-Dibenzylethylenediammonium bis[(6R)-6-(2-phenylacetamido)-
penicillanate]; Permapen; Strepdipen-Suspension; Tardocillin; Vicin
Molecular formula (C16H18N2O4S)2.C16H20N2
Molecular weight 909
Structural formula
N
O
N
H
CH3S
CH3
CO2H
C
O
CH2
N
H
CH2CH2 CH2
N
O
N
H
CH3 S
CH3
HO2C
C
O
CH2
N
H
CH2
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 3689-73-4
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-[(phenylacetyl)amino]- [2S-(2a,5a,6b)]-, 2-(diethylamino)ethyl
ester
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-(2-phenylacetamido)-, 2-(diethylamino)ethyl ester (8CI)
Penicillin G, 2-(diethylamino)ethyl ester (6CI, 7CI)
Synonyms/Trade
names
Benzylpenicillin .beta.-diethylaminoethyl ester; Ephicillin; Penethamate;
Penicillin G diethylaminoethyl ester
Molecular formula C22H31N3O4S
Molecular weight 434
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
O
CH2
CH2 CH2 N
CH2
CH2
CH3
CH3
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 6130-64-9
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-[(phenylacetyl)amino]- [2S-(2a,5a,6b)]-, compd. With 2-
(diethylamino)ethyl 4-aminobenzoate (1:1), monohydrate
Other chemical index
names
Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester, mono[[2S-
(2.a,5a,6b)]-3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate], monohydrate (9CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-
oxo-6-(2-phenylacetamido)-, compd. with 2-(diethylamino)ethyl p-
aminobenzoate (1:1), monohydrate (8CI)
Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester, mono[3,3-dimethyl-
7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-
carboxylate], monohydrate (8CI)
Synonyms/Trade
names
2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacet-
amido)penicillinate monohydrate; Procaine Penicillin; Abbocillin-DC;
Afsillin; Ampin-pencillin; Aqucilina; Aquacillin; Aquasuspen;
Avloprocil; Ayercillin; Benzylpenicillin procaine monohydrate; Cilicaine;
Cilicaine Syringe; Cilina 900; Crysticillin; Depocillin; Despacilina;
Distaquaine; Duracillin; Farmaproina; Flo-Cillin Aqueous; Kabipenin;
Ledercillin; Millicillin; Mylipen; Neoproc; Novocaine penicillin;
Novocillin; Pen-Fifty; Penaquacaine G; Pfizerpen-AS; Premocillin; Pro-
Pen; Procaina; Procaine penicillin G hydrate; Procaine penicillin G
monohydrate; Procanodia; Procillin; Prostabillin; Provipen; Quick-
Cillin;Sharcillin; Wycillin
Molecular formula C16H18N2O4S.C13H20N2O2.H2O
Molecular weight 589
Structural formula
N
O
N
H
CH3S
CH3
CO2H
C
O
CH2 CO2 CH2 N
CH2
CH2
H2N
CH2
CH3
CH3
OH2
Physical state at 25°C Solid white crystalline powder
Solubility 1 in 250 (water)
1 in 30 (ethanol)
1 in 60 (chloroform)
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 7081-44-9
Chemical index name
(CA 9th CI)Chemical
name
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2-chloro-
phenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-,
monosodium salt, monohydrate, [2S-(2a,5a,6b)]-
Other chemical index
name
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[3-(o-chloro-
phenyl)-5-methyl-4-isoxazolecarboxamido]-3,3-dimethyl-7-oxo-,
monosodium salt, monohydrate (8CI)
Synonyms/Trade
names
Cloxacillin sodium monohydrate; Clocillin monohydrate; Cloxapen
monohydrate; Sodium cloxacillin monohydrate
Molecular formula C19H17ClN3O5S.Na.H2O
Molecular weight 476
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
OCl
CH3O
N
-
Na+ OH2
Physical state at 25°C Solid white almost white powder
Solubility 1 in 2.5 (water)
1 in 30 (ethanol)
Remarks Multi-ingredient preparations: Ampiclox, Amplium
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 13412-64-1
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2,6-dichlo-
rophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-,
monosodium salt, monohydrate, [2S-(2a,5a,6b)]-
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[3-(2,6-dichloro-
phenyl)-5-methyl-4-isoxazolecarboxamido]-3,3-dimethyl-7-oxo-,
monosodium salt, monohydrate (8CI);
Synonyms/Trade
names
3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolyl penicillin sodium,
monohydrate; Blp-1011; Brispen; Brl-1702; Constaphyl; Dichlor-
stapenor; Dichlorstapenor sodium; Diclocil; Dicloxacillin, sodium;
Dicloxacillin sodium hydrate; Dicloxacillin sodium monohydrate;
Dicloxacillin sodium salt; Dicloxacillin sodium salt hydrate; Dycill;
Dynapen; Mdi-pc; Noxaben; P 1011; Pathocil; Pen-sint; Sodium
dicloxacillin; Sodium dicloxacillin hydrate; Sodium dicloxacillin
monohydrate; Stampen; Staphcillin a banyu; Syntarpen; Veracillin
Molecular formula C19H16Cl2N3O5S.Na.H2O
Molecular weight 510
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
OCl
CH3O
N
-
Na+Cl OH2
Physical state at 25°C Solid white or almost white hygroscopic crystalline powder
Solubility Freely soluble in water, soluble in alcohol
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 17243-38-8
Chemical name (CA
9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(azidophenyl-
acetyl)amino]-3,3-dimethyl-7-oxo-, [2S-[2a,5a,6b(S*)]]
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(2-azido-2-
phenylacetamido)-3,3-dimethyl-7-oxo-, D-(-)- (8CI)
Synonyms/Trade
names
Azidocillin; BRL 2534; D-(-)-.alpha.-Azidobenzylpenicilin; DAN 10510;
Globacillin; SPC 297D
Molecular formula C16H17N5O4S
Molecular weight 375
Structural formula
N
O
N
H
CH3S
CH3
CO2H
C
O
C
N3
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 26309-95-5
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-
oxopropoxy)methyl ester, monohydrochloride [2S-[2a,5a,6b (S*)]]
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(2-amino-2-
phenylacetamido)-3,3-dimethyl-7-oxo-, hydroxymethyl ester pivalate
(ester), monohydrochloride, D- (8CI);
Methanediol, 6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]heptane-2-carboxylate pivalate (ester),
monohydrochloride (8CI);
Pivalic acid, hydroxymethyl ester 6-(2-amino-2-phenylacetamido)-3,3-
dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate,
monohydrochloride (8CI)
Synonyms/Trade
names
Alphacilina; Alphacillin; 6-(d-alpha-Aminophenylacetamido)penicillanic
acid pivaloyloxymethyl ester; Hydrochloride; Ampicillin pivaloyloxy-
methyl ester hydrochloride; Ampicillin pivaloxyoxymethyl ester
hydrochloride; Berocillin; Centurina; Devonium; Diancina; Inacilin;
Maxifen; Pivaloyloxymethyl d-alpha-aminobenzylpenicillinate hydro-
chloride; Pivaloyloxymethyl ampicillinate; Pivaloyloxymethyl D-(-)-
.alpha.-aminophenylacetamidopenicillanate; Pivampicillin hydrochloride;
Pivatil; Pondocil; Pondocillin; Sanguicillin
Molecular formula C22H29N3O6S.HCl
Molecular weight 500
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
O
CH
NH2
C
O
CH2 O C
CH3
CH3
CH3 ClH
Remarks Pondocillin is used for prepartion of tablets but not for granules
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 32886-97-8
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(hexahydro-1H-
azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-
oxopropoxy)methyl ester, [2S-(2a,5a,6b)]-
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(hexahydro-1H-
azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, hydroxymethyl ester
pivalate (ester), (+)- (8CI)
Synonyms/Trade
names
Amdinocillin pivoxil; FL 1039; Pivaloyloxymethyl (6R)-6-(perhydroaze-
pin-1-ylmethyleneamino)penicillanate; Pivamdinocillin; Pivmecillinam
more see Pivmecillinam; Selexid
Molecular formula C21H33N3O5S
Molecular weight 440
Structural formula
N
O
N CH3S
CH3
CO2
CH
C
O
CH2 O C
CH3
CH3
CH3
N
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 32887-01-7
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(hexahydro-1H-
azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, [2S-(2a,5a,6b)]-
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(hexahydro-1H-
azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, (+)- (8CI)
6-(perhydroazepin-1-ylmethyleneamino)penicillanic acid
4-Thia-1-Azabicyclo(3.2.0)Heptane-2-Carboxylic Acid,
6-(((Hexahydro-1h-Azepin-1-Yl)Methylene) Amino)-3,3-Dimethyl-7-
Oxo-, (+)-
Synonyms/Trade
names
6-((Hexahydro-1h-Azepin-1-Yl)Methyleneamino)Penicillanic Acid;
Amdinocillin; Fl 1060; Hexacillin; Hexapen; Mecilinamo; Mecillinam;
Penicillin Hx; Ro 10-9070; Selecidin; Selexid; Selexidin;
Molecular formula C15H23N3O3S
Molecular weight 325
Structural formula
N
O
N CH3S
CH3
CO2H
CHN
52
Chemical and physical properties of penicillins used in Sweden.
CAS No. 32887-03-9
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(hexahydro-1H-
azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-
oxopropoxy)methyl ester, monohydrochloride, [2S-(2a,5a,6b)]-
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(hexahydro-1H-
azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, hydroxymethyl ester
pivalate (ester), monohydrochloride, (+)- (8CI)
Synonyms/Trade
names
FL-1039; Melysin; Pivaloyloxymethyl (6R)-6-(perhydroazepin-1-
ylmethyleneamino)penicillana te hydrochloride; Pivmecilinamo
clorhidrato; Pivmecillinam Hydrochloride; Selexid
Molecular formula C21H33N3O5S.HCl
Molecular weight 476
Structural formula
N
O
N CH3S
CH3
CO2
CH
C
O
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CH3
CH3
CH3 ClH
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 33817-20-8
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenyl-
acetyl)amino]-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl
ester, [2S-[2a,5a,6b(S*)]]-
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(2-amino-2-
phenylacetamido)-3,3-dimethyl-7-oxo-, hydroxymethyl ester pivalate
(ester), D-(-)- (8CI)
Synonyms/Trade
names
Alphacillin; Ampicillin pivaloyloxymethyl ester; MK 191; Pivaloyl-
ampicillin; Pivaloyloxymethyl ampicillinate; Pivaloyloxymethyl D-
.alpha.-aminobenzylpenicillinate; Pivampicillin*, Pondocillin**
Molecular formula C22H29N3O6S
Molecular weight 464
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
O
CH
NH2
C
O
CH2 O C
CH3
CH3
CH3
Remarks Granulate is not called Pondocillin
*Pondocillin is used as the product preparations name in Sweden though
Pondocillin is the HCl salt of pivampicillin (CAS No. 26309-95-5)
according to (RTECS)
**According to RTECS this preparation contains pivampicillin HCl
[26309-95-5]
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 37661-08-8
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenyl-
acetyl)amino]-3,3-dimethyl-7-oxo-, 1-[(ethoxycarbonyl)oxy]ethyl ester,
monohydrochloride, [2S-[2a,5a,6b(S*)]]-
4
Synonyms/Trade
names
Ambacamp; Ambaxin; Bacacil; Bacampicillin hydrochloride; BAPC;
Becampicillin; Becampicillin hydrochloride; Penglobe; Spectrobid
Molecular formula C21H27N3O7S.HCl
Molecular weight 502
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
O
CH
NH2
C
O
CH O O CH2
CH3
CH3 ClH
Physical state at 25°C Solid white or practically white powder
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 58486-36-5
Chemical index name
(CA 9th CI)
Magnesium, bis[6-[[[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]-
carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-
2-carboxylato-O2,O7]-, [T-4-[2S-(2a,5a,6b)], [2S-(2a,5a,6b)]]-
Other chemical index
names
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2-chloro-6-
fluorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-
oxo-, magnesium complex, [2S-(2a,5a,6b)]-
Synonyms/Trade
names
Heracillin®; Magnesium flucloxacillin; Flucloxacillin, magnesum
Molecular formula (C19H16ClFN3O5S)2.Mg.8H2O
Molecular weight 1074
Structural formula
N
O
N
H
CH3S
CH3
CO2
C
OF
CH3O
N
-
Mg2+
Cl
N
O
N
H
CH3S
CH3
CO2
C
OF
CH3ON
-
Cl
OH28
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Chemical and physical properties of penicillins used in Sweden.
CAS No. 61336-70-7
Chemical index name
(CA 9th CI)
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino(4-
hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, trihydrate, [2S-[2a,
5a,6b(S*)]]-
Synonyms/Trade
names
alpha-Amino-p-hydroxybenzylpenicillin trihydrate; Amimox; Amoxicillin
NM Pharm; Amoxicillin trihydrate; Amoxycillin trihydrate; Bristamox*;
BRL 2333 trihydrate; Imacillin;
Molecular formula C16H19N3O5S,3H2O
Molecular weight 419
Structural formula
N
O
N
H
CH3S
CH3
CO2H
C
O
CH
NH2
HO
OH23
Physical state at 25°C Solid white (or almost white) crystalline powder
Partition Coefficient
(Log P(octanol)**
0.87
Solubility 1 in 400 (water)
1 in 1000 (ethanol)
practically insoluble in chloroform and ether
Remarks *According to RTECS this preparations contains amoxicillin [26787-78-
0] but the preparation sold in Sweden contains amoxicillin trihydrate
[61336-70-7].
**Codex 1994 p.729
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Appendix 2
Products that may cause potential penicillin exposure in the pharmacy: preparation of oral
liquids.
Trade Namea Type of product Described State2 Marketing company
Phenoxymethylpenicillin (CAS No.: 132-98-9)
Kåvepenin® Mixture Solid, granulate Astra, Sweden
Kåvepenin®b Dose granulate Solid, granulate Astra, Sweden
Kåvepenin® Drops Solid, granulate Astra, Sweden
Amoxicillin trihydrate (CAS No.: 61336-70-7)
Amimox® Mixture Solid, granulate Tika, Sweden
Amoxicillin Scand
Pharma
Mixture Solid, granulate Scand Pharma,
Sweden
Imacillin® Mixture Solid, granulate Astra, Sweden
Spetramox®b Mixture Solid, granulate Astra, Sweden
Dicloxacillin sodium monohydrate (CAS No.: 13412-64-1)
Diclocil Mixture Solid, powder Bristol-Myers Squibb
Pivamecillinam (CAS No.: 32886-97-8)
Selexid® Dose granulate Solid, granulate Leo Pharma
Pivampicillin (CAS No.: 33817-20-8)
Pondocillin® Mixture Solid, granulate Leo Pharma
Pondocillinb Dose granulate Solid, granulate Leo Pharma
Flucloxcillin (CAS No.: 58486-36-5)
Heracillin® Mixture Ndc Astra, Sweden
a Information taken from (53).
b Single dose granulate preparation is available for consumer to mix.
c Nd = not detailed
